The upside of this checkpoint protein overexpression phenotype is the strong efficacy of immune checkpoint inhibitor therapies that have shown positive outcomes in MMR-deficient tumours across a range of malignancies [40]. This evidence concerns the gene MRC1 and neoplasm.